Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Current Deferred Revenue (2018 - 2025)

RedHill Biopharma has reported Current Deferred Revenue over the past 8 years, most recently at $6.3 million for Q4 2025.

  • Quarterly Current Deferred Revenue fell 32.13% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.3 million through Dec 2025, down 32.13% year-over-year, with the annual reading at $6.3 million for FY2025, 32.13% down from the prior year.
  • Current Deferred Revenue was $6.3 million for Q4 2025 at RedHill Biopharma, down from $10.5 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $47.9 million in Q4 2022 and troughed at $6.3 million in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $26.0 million (2023), against an average of $24.0 million.
  • Year-over-year, Current Deferred Revenue skyrocketed 67.43% in 2021 and then tumbled 77.74% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $30.7 million in 2021, then skyrocketed by 55.87% to $47.9 million in 2022, then tumbled by 77.74% to $10.7 million in 2023, then fell by 12.82% to $9.3 million in 2024, then crashed by 32.13% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Current Deferred Revenue are $6.3 million (Q4 2025), $10.5 million (Q2 2025), and $9.3 million (Q4 2024).